- Case report
- Open Access
- Open Peer Review
Synchronous well differentiated neuroendocrine tumour and gastrointestinal stromal tumour of the stomach: a case report
© Samaras et al; licensee BioMed Central Ltd. 2011
- Received: 25 October 2010
- Accepted: 24 March 2011
- Published: 24 March 2011
Well differentiated neuroendocrine tumours (carcinoids), arising from cells of the diffuse neuroendocrine system, represent the most commonly encountered gastric endocrine tumours. Gastrointestinal stromal tumours (GISTs), which stem from interstitial Cajal cells located within the wall of the gastrointestinal tract and have a characteristic immunoreactivity for CD117 (c-kit protein), account for the majority of gastrointestinal mesenchymal neoplasms. Simultaneous occurrence of a GIST with a well differentiated neuroendocrine tumour in the stomach is very rare.
Clinical history, endoscopy and histopathological findings were utilized for our diagnostic considerations.
We report the coexistence of a high risk GIST with a well differentiated neuroendocrine tumour of benign clinical behavior, both located in the stomach, in a 62-year-old man previously operated for a gastric well differentiated neuroendocrine tumour with uncertain malignant behaviour.
Even single well differentiated, sporadic, NETs of small size may coexist with GISTs. An appropriate initial therapeutic approach combined with a scrupulous follow-up seems to play a significant role in terms of preventing a metastatic disease.
- neuroendocrine tumour
Gastrointestinal neuroendocrine tumours (NETs) are thought to derive from cells of the diffuse neuroendocrine system of the gastrointestinal (GI) tract . In the stomach, most endocrine tumours are located in the corpus or fundus, constituting a group of nonfunctioning, enterochromaffin-like (ECL) cell, well differentiated NETs (carcinoids). Gastric NETs are divided into four types: a) type I, associated with autoimmune chronic atrophic gastritis (A-CAG), b) type II, linked to multiple endocrine neoplasia type 1 (MEN-1) or to the Zollinger-Ellison syndrome (ZES) and c) type III, sporadic, unrelated to hypergastrinemia or A-CAG, d) type IV, representing a heterogeneous group of tumours which show evidence of multidirectional differentiation, such as a combination of adenocarcinoma and NET [2–4].
Gastrointestinal stromal tumours (GISTs) are mesenchymal neoplasms stemming from the interstitial cells of Cajal localized within the wall of the GI tract [5, 6]. GISTs show a predilection for the stomach, where they constitute the majority of mesenchymal tumours [7, 8]. Immunopositivity for CD117 (c-kit protein) is a distinctive immunohistochemical feature of these tumours [8, 9], for which tumour size and mitotic activity are the most significant parameters regarding prediction of clinical behavior [10, 11].
GISTs have been reported to coexist with a variety of neoplasms, the percentage of such cases ranging from 4.5% to 33% [12, 13]; in such cases, the stomach is the most frequent location of GIST . The most common coexisting tumour is adenocarcinoma of the gastrointestinal tract [12, 13]; other types include lymphoma, leukemia, carcinomas of breast, prostate, pancreas or lung or adrenocortical adenoma [12–16]. Similarly, previous studies have shown an association between GI NETs and synchronous or metachronous epithelial tumours accounting for about 10% to 46% of cases [17, 18].
What is more, coexistence of GISTs with gastrointestinal tract endocrine tumours, such as ileal well differentiated NET  or well differentiated NET of the pancreas  has also been reported. However, the simultaneous occurrence of gastric well differentiated NET and gastric GIST seems to be rare, a handful of cases having so far been reported, to our best knowledge [7, 9, 12, 20].
In this context, we hereby present the case of synchronous occurrence of a GIST and a well differentiated NET, both located in the stomach of a male patient. Our report seems to be distinctive as it comprises unique clinical and histopathological findings.
However, four years post-op, CT showed a well delineated, 3.5 cm large, intramural lesion in the esophagogastric junction. Serum gastrin levels were within normal limits. The patient underwent excision of the remaining part of the stomach; this corresponded to a subtotal gastrectomy (with subsequent reconstruction of the GI tract) specimen with a 35 cm long greater and a 14.5 cm long lesser curvature, respectively, together with a 1.9 cm long duodenal cuff. A stenosis was observed in the incisura angularis; moreover, a protruding, multilobular, 3.5 cm large tumour was located close to the esophagogastric junction, on the anterior wall of the stomach, presenting, upon sections, a whitish color with brownish foci and a fibrous consistency. The remaining gastric mucosa was unremarkable.
Of the previous reports regarding the simultaneous occurence of GIST and well differentiated NET in the stomach we achieved to retrieve data only for three cases. Specifically, one case concerned a 69-year old male with negative family history of cancer who underwent removal of a sessile polypoid mass in the corpus of the stomach. Histological examination of the resected specimen demonstrated a submucosal borderline GIST, while in the overlying mucosa a well differentiated NET (carcinoid), invading the lamina propria and initially infiltrating the submucosa, was recognized. Neither H. pylori microorganisms nor foci of intestinal metaplasia were identified in the surrounding mucosa. The patient died of unrelated cause (heart attack) twelve months after the surgical intervention, while imaging findings were all negative concerning metastatic deposits from the above-mentioned lesions .
The second case concerned a 65-year-old female with a low-risk GIST on the anterior wall of the upper gastric corpus concomitant with a type III well differentiated NET localized on the posterior wall of the upper gastric corpus; no recurrence of either tumour occurred 28 months after excision . In the third case a 65-year-old female, who had previously undergone subtotal gastrectomy for a GIST (risk category not mentioned), presented with serum hypergastrinemia and polypoid lesions of the gastric stump, a year post-op. Histology showed polypoid type I gastric well differentiated NETs, while the histopathological examination of the remaining stomach's excision specimen documented the co-existence of a GIST (risk category not mentioned) . Agaimy et al., also, based on their own archives and on data collected from the literature, reported four gastric well differentiated NETs concurrent with GISTs .
Regarding pathogenetic mechanisms implicated in the dual development of GIST and well differentiated NET in the stomach, data are still insufficient. Though a role of H. pylori infection cannot be excluded, it is at present not clear, perhaps due to the small number of cases so far reported. Thus, Lin et al. did not conclude any definite causal relationship among GIST, well differentiated NET and H. pylori infection , a point also valid in our case, where no H. pylori was shown. The hypothesis which is based on experimental data in rats and supports the notion that a single carcinogenic agent possibly interacts with two neighboring tissues, inducing the development of tumours of different histotypes in the same organ, remains to be substantiated in human tissues [25–27]. In addition, we cannot entirely exclude the possibility that genetic factors concerning specific gene mutations could be responsible for the synchronous development of two gastric tumours. On the other hand, a coincidental growth of two primary neoplasms in the same organ (stomach) could be also a possible consideration. Further studies are certainly needed in order to elucidate this phenomenon.
Gastric well differentiated NETs account for 8.7-41% of all gastrointestinal well differentiated NETs . Their clinical features include abdominal pain, vomiting, anemia, massive gastric bleeding or, rarely, carcinoid syndrome [2, 27]. Our patient had an episode of melena preceding the diagnosis of its first well differentiated NET, whereas the second one was incidentally diagnosed.
In our report, both well differentiated NETs were single lesions; despite the fact that the first tumour arose in the context of endocrine cell hyperplasia, the absence of serum autoimmunity indices precludes its classification as a type I gastric well differentiated NET; both tumours, therefore, correspond to type III according to the WHO classification [2–4].
According to the WHO classification, benign behavior of well differentiated NETs is associated with the following criteria: cytologically bland tumour confined to mucosa and/or submucosa, non-angioinvasive, less than 1 cm in size, non-functioning; these features are mainly found in tumours arising in the context of A-CAG or MEN-1/ZES. On the contrary, uncertain malignant behavior of well differentiated NETs is associated with a nonfunctioning, cytologically bland tumour, measuring 1 to 2 cm in diameter, confined to the mucosa and/or submucosa. Angioinvasion may be present in these lesions [2, 21–23]. This category comprises some of the type II gastric NETs. Therefore, in our case, the first neuroendocrine tumour was diagnosed with uncertain malignant behaviour due to its size and its being single.
Limited surgical interventions (including endoscopic manipulations) remain the mainstay treatment for type I gastric well differentiated NETs . Partial gastrectomy combined with appropriate treatment for concomitant hypergastrinemia is necessary for type II neoplasms . Finally, a total gastrectomy is counseled for type III well differentiated NETs, even when they are histologically well differentiated, particularly in tumours larger than 1 cm [2, 29], a treatment not initially performed in our case, due to the patient's refusal.
GISTs, thought to arise from interstitial Cajal cells of the gastrointestinal wall [5, 6], demonstrate no clear gender predilection; affected individuals are mainly adults between the 6th and 8th decade . Gastric GISTs can be incidentally detected during endoscopy, an imaging study or in a surgical specimen, given that they are slowly growing tumours localized within deeper layers of gastrointestinal wall. Though our patient was asymptomatic, GISTs usually manifest with nonspecific symptoms, such as nausea, vomiting, abdominal pain or, most often, with bleeding, due to protrusion of the tumour and stretching of the overlying mucosa; metastasis may sometimes constitute the initial symptom [8, 9].
Concerning prediction of clinical behavior, the initial proposal formulated by the National Institute of Health (NIH) GIST Workshop in 2001 defined the risk for aggressive behavior based on tumour size (single largest dimension) and mitotic count (number of mitotic figures per 50 HPF) , classifying GISTs into very low, low, intermediate and high risk categories. More recently, the Armed Forces Institute of Pathology (AFIP) suggested a new risk stratification of primary GISTs, introducing the site involved alongside the two criteria previously mentioned, i.e. mitotic index and size ; thus, gastric GISTs are stratified as having none, very low, low, moderate or high risk of progressive disease. Regardless of the system used, it should be kept in mind that large tumours (especially those larger than 10 cm), even when having no detectable mitotic activity, may show late recurrences and even metastatic deposits. According to the WHO guidelines, DNA-aneuploidy and high proliferative activity, assessed by proliferation markers, may reflect higher malignant potential . In our case, the GIST was classified as of moderate risk according to the AFIP criteria, whereas it corresponded to the high risk category according to the NIH criteria.
In conclusion, we presented a rare case of a well differentiated NET concurrent with a GIST in the stomach. Gastroenterologists and pathologists, in particular, should be aware of this rare phenomenon given that even single well differentiated, sporadic (unrelated to hypergastrinemia or A-CAG), NETs of small size may coexist with GISTs, as it was shown in our case. A meticulous follow-up (along with a well scheduled initial therapeutic approach) should be performed to all patients suffering from the afore-mentioned neoplasms so as the devastating consequences of a metastatic disease to be avoided.
Written informed consent was obtained from the patient for publication purposes.
- Jensen RT: Neuroendocrine tumors of the gastrointestinal tract and pancreas. >Harrison's Principles of Internal Medicine. Edited by: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. 2005, New York: McGraw-Hill, 2220-2226. 16Google Scholar
- Capella C, Solcia E, Sobin LH, Arnold R: Endocrine tumours of the stomach. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Edited by: Hamilton SR, Aaltonen LA. 2000, Lyon: IARC Press, 53-57.Google Scholar
- Solcia E, Rindi G, Larosa S, Capella C: Morphological, molecular, and prognostic aspects of gastric endocrine tumors. Microsc Res Tech. 2000, 48: 339-348. 10.1002/(SICI)1097-0029(20000315)48:6<339::AID-JEMT4>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Waisberg J, de Matos LL, do Amaral Antonio Mader AM, et al: Neuroendocrine gastric carcinoma expressing somatostatin: A highly malignant, rare tumor. World J Gastroenterol. 2006, 12: 3944-3947.View ArticlePubMedPubMed CentralGoogle Scholar
- Robinson TL, Sircar K, Hewlett BR, Chorneyko K, Riddell RH, Huizinga JD: Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol. 2000, 156: 1157-1163. 10.1016/S0002-9440(10)64984-X.View ArticlePubMedPubMed CentralGoogle Scholar
- Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH: Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol. 1999, 23: 377-389. 10.1097/00000478-199904000-00002.View ArticlePubMedGoogle Scholar
- Hung CY, Chen MJ, Shih SC, Liu TP, Chan YJ, Wang TE, et al: Gastric carcinoid tumor in a patient with a past history of gastrointestinal stromal tumor of the stomach. World J Gastroenterol. 2008, 14 (44): 6884-7. 10.3748/wjg.14.6884.View ArticlePubMedPubMed CentralGoogle Scholar
- Miettinen M, Blay JY, Sobin LH: Mesenchymal tumours of the stomach. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Digestive System. Edited by: Hamilton SR, Aaltonen LA. 2000, Lyon: IARC Press, 62-65.Google Scholar
- Lin YL, Wei CK, Chiang JK, Chou AL, Chen CW, Tseng CE: Concomitant gastric carcinoid and gastrointestinal stromal tumors: a case report. World J Gastroenterol. 2008, 14 (39): 6100-3. 10.3748/wjg.14.6100.View ArticlePubMedPubMed CentralGoogle Scholar
- Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol. 2002, 33 (5): 459-65. 10.1053/hupa.2002.123545.View ArticlePubMedGoogle Scholar
- Miettinen M, Lasota J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006, 23 (2): 70-83. 10.1053/j.semdp.2006.09.001.View ArticlePubMedGoogle Scholar
- Agaimy A, Wünsch PH, Sobin LH, Lasota J, Miettinen M: Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 2006, 23 (2): 120-9. 10.1053/j.semdp.2006.09.004.View ArticlePubMedGoogle Scholar
- Liszka L, Zielinska-Pajak E, Pajak J, Golka D, Huszno J: Coexistence of gastrointestinal stromal tumors with other neoplasms. J Gastroenterol. 2007, 42: 641-649. 10.1007/s00535-007-2082-4.View ArticlePubMedGoogle Scholar
- Kövér E, Faluhelyi Z, Bogner B, Kalmár K, Horváth G, Tornóczky T: Dual tumours in the GI tract: synchronous and metachronous stromal (GIST) and epithelial/neuroendocrine neoplasms (in Hungarian with English abstract). Magy Onkol. 2004, 48 (4): 315-21.PubMedGoogle Scholar
- Melis M, Choi EA, Anders R, Christiansen P, Fichera A: Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST). Int J Colorectal Dis. 2007, 22: 109-114. 10.1007/s00384-006-0089-6.View ArticlePubMedGoogle Scholar
- Kimura M, Irie A, Minei S, Ishii J, Okawa A, Takashima R, et al: A case of adrenocortical adenoma coexisting with gastrointestinal stromal tumor (in Japanese with English abstract). Hinyokika Kiyo. 2007, 53 (8): 551-5.PubMedGoogle Scholar
- Cirillo F: Neuroendocrine tumors and their association with rare tumors: observation of 4 cases. Eur Rev Med Pharmacol Sci. 2010, 14 (7): 577-88.PubMedGoogle Scholar
- Habal N, Sims C, Bilchik AJ: Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol. 2000, 75: 301-6. 10.1002/1096-9098(200012)75:4<306::AID-JSO14>3.0.CO;2-3.View ArticleGoogle Scholar
- Buragas M, Kidd M, Modlin IM, Cha C: Multiple gastrointestinal stromal tumors and synchronous ileal carcinoids. Nat Clin Pract Oncol. 2005, 2 (3): 166-70. 10.1038/ncponc0108. quiz 1 p following 170View ArticlePubMedGoogle Scholar
- Maiorana A, Fante R, Maria Cesinaro A, Adriana Fano R: Synchronous occurrence of epithelial and stromal tumors in the stomach: a report of 6 cases. Arch Pathol Lab Med. 2000, 124 (5): 682-6.PubMedGoogle Scholar
- Capella C, Heitz PU, Hofler H, et al: Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion. 1994, 55 (Suppl 3): 11-23. 10.1159/000201197.PubMedGoogle Scholar
- Kloppel G, Heitz PU, Capella C, Solcia E: Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions. World J Surg. 1996, 20: 132-141. 10.1007/s002689900021.View ArticlePubMedGoogle Scholar
- Solcia E, Capella C, Klöppel G, et al: Histological Typing of Endocrine Tumours. Endocrine tumours of the gastrointestinal tract. World Health Organization International Histological Classification of Tumours. Edited by: Solcia E, Klöppel G, Sobin LH. 2000, Berlin: Springer-Verlag, 61-68. 2Google Scholar
- Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al: American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373 (9669): 1097-104. 10.1016/S0140-6736(09)60500-6. Erratum in: Lancet 2009, 374(9688):450View ArticlePubMedPubMed CentralGoogle Scholar
- Sugimura T, Fujimura S, Baba T: Tumor production in the glandular stomach and alimentary tract of the rat by N-methyl-N9-nitro-N-nitrosoguanidine. Cancer Res. 1970, 30: 455-465.PubMedGoogle Scholar
- Cohen A, Geller SA, Horowitz I, Toth LS, Werther JL: Experimental models for gastric leiomyosarcoma: the effects of N-methyl-N9-nitro-N-nitrosoguanidine in combination with stress, aspirin, or sodium taurocholate. Cancer. 1984, 53: 1088-1092. 10.1002/1097-0142(19840301)53:5<1088::AID-CNCR2820530512>3.0.CO;2-Y.View ArticlePubMedGoogle Scholar
- Roncoroni L, Costi R, Canavese G, Violi V, Bordi C: Carcinoid tumor associated with vascular malformation as a cause of massive gastric bleeding. Am J Gastroenterol. 1997, 92: 2119-2121.PubMedGoogle Scholar
- Ichikawa J, Tanabe S, Koizumi W, Kida Y, Imaizumi H, Kida M, et al: Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003, 35: 203-206. 10.1055/s-2003-37256.View ArticlePubMedGoogle Scholar
- Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L: Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005, 242: 64-73. 10.1097/01.sla.0000167862.52309.7d.View ArticlePubMedPubMed CentralGoogle Scholar
- Duffaud F, Blay JY: Gastrointestinal stromal tumors: biology and treatment. Oncology. 2003, 65: 187-197. 10.1159/000074470.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/11/27/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.